<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04436653</url>
  </required_header>
  <id_info>
    <org_study_id>TRAVEL</org_study_id>
    <nct_id>NCT04436653</nct_id>
  </id_info>
  <brief_title>THE TRAVEL TRIAL: Transcatheter Right Atrial-ventricular Valve rEplacement With LuX-Valve</brief_title>
  <acronym>TRAVEL</acronym>
  <official_title>THE TRAVEL TRIAL: Transcatheter Right Atrial-ventricular Valve rEplacement With LuX-Valve</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changhai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fu Wai Hospital, Beijing, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Anzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangdong Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Changhai Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial aims to evaluate the safety and effectiveness of LuX-Valve transcatheter tricuspid&#xD;
      valve and delivery system which are intended to use in symptomatic patients with severe&#xD;
      tricuspid regurgitation and high surgical risk.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The TRAVEL study is a prospective multi-center single-arm trial for transcatheter tricuspid&#xD;
      valve replacement with LuX-Valve. A series of physical, imaging and laboratory exams will be&#xD;
      performed to determine whether a subject has severe tricuspid regurgitation with high&#xD;
      surgical risk. Subjects who meet the criteria will then receive LuX-Valve implantation if an&#xD;
      informed consent is obtained.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 16, 2020</start_date>
  <completion_date type="Anticipated">June 2026</completion_date>
  <primary_completion_date type="Anticipated">June 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a prospective, multi-center single-arm trial in seven centers in China. A minimum of 150 subjects will be enrolled in this study and followed-up at discharge (≤ 10 days post operation), 30 days, 6 months, 1, 2, 3, 4, 5 years.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>1 Year</time_frame>
    <description>All-cause Death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tricuspid Regurgitation Reduction</measure>
    <time_frame>1 Year</time_frame>
    <description>Tricuspid regurgitation measured with echocardiography in core lab reduces at least 2 grades.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device or Procedure-Related Adverse Events</measure>
    <time_frame>1 Year</time_frame>
    <description>Device related mortality, device malposition, right ventricular outflow tract obstruction, conduction system disturbances, new onset shunt across ventricular septum, coronary artery injury, valve failure, convert to open surgery, reintervention, embolization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device or Procedure-Related Adverse Events</measure>
    <time_frame>2 Year</time_frame>
    <description>Device related mortality, device malposition, right ventricular outflow tract obstruction, conduction system disturbances, new onset shunt across ventricular septum, coronary artery injury, valve failure, convert to open surgery, reintervention, embolization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device or Procedure-Related Adverse Events</measure>
    <time_frame>3 Year</time_frame>
    <description>Device related mortality, device malposition, right ventricular outflow tract obstruction, conduction system disturbances, new onset shunt across ventricular septum, coronary artery injury, valve failure, convert to open surgery, reintervention, embolization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device or Procedure-Related Adverse Events</measure>
    <time_frame>4 Year</time_frame>
    <description>Device related mortality, device malposition, right ventricular outflow tract obstruction, conduction system disturbances, new onset shunt across ventricular septum, coronary artery injury, valve failure, convert to open surgery, reintervention, embolization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device or Procedure-Related Adverse Events</measure>
    <time_frame>5 Year</time_frame>
    <description>Device related mortality, device malposition, right ventricular outflow tract obstruction, conduction system disturbances, new onset shunt across ventricular septum, coronary artery injury, valve failure, convert to open surgery, reintervention, embolization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Event (MAE)</measure>
    <time_frame>1 Year</time_frame>
    <description>MAE includes death, myocardial infarction, stroke, reoperation for bleeding, renal failure, pulmonary embolism, gastrointestinal hemorrhage, rehospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Event (MAE)</measure>
    <time_frame>2 Year</time_frame>
    <description>MAE includes death, myocardial infarction, stroke, reoperation for bleeding, renal failure, pulmonary embolism, gastrointestinal hemorrhage, rehospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Event (MAE)</measure>
    <time_frame>3 Year</time_frame>
    <description>MAE includes death, myocardial infarction, stroke, reoperation for bleeding, renal failure, pulmonary embolism, gastrointestinal hemorrhage, rehospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Event (MAE)</measure>
    <time_frame>4 Year</time_frame>
    <description>MAE includes death, myocardial infarction, stroke, reoperation for bleeding, renal failure, pulmonary embolism, gastrointestinal hemorrhage, rehospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Event (MAE)</measure>
    <time_frame>5 Year</time_frame>
    <description>MAE includes death, myocardial infarction, stroke, reoperation for bleeding, renal failure, pulmonary embolism, gastrointestinal hemorrhage, rehospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Change in New York Heart Association (NYHA) Classification</measure>
    <time_frame>1 Year</time_frame>
    <description>Subjects' heart function is ranged from NYHA I to IV based on how much a patient is limited during physical activity. NYHA I means no limited on physical activity while NYHA IV means unable to take any physical activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life (QOL) is evaluated with Kansas City Cardiomyopathy (KCCQ)</measure>
    <time_frame>1 Year</time_frame>
    <description>KCCQ score ranges from 0 to 100, which 0 reflects the worst health status and 100 reflects the best health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life (QOL) is evaluated with Six Minute Walk Test (6MWT)</measure>
    <time_frame>1 Year</time_frame>
    <description>6MWT distance is recorded and compared with baseline during follow-up.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Tricuspid Valve Insufficiency</condition>
  <arm_group>
    <arm_group_label>Tricuspid Valve Replacement System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who received transcatheter tricuspid valve replacement with LuX-Valve and delivery system will be included in this arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tricuspid Valve Replacement System</intervention_name>
    <description>To eliminate the tricuspid regurgitation through orthotopically replacing tricuspid valve with LuX-Valve system.</description>
    <arm_group_label>Tricuspid Valve Replacement System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 50 years at time of consent.&#xD;
&#xD;
          2. Subjects or subject's legal representative has been informed of the nature of the&#xD;
             study and provided written informed consent.&#xD;
&#xD;
          3. The site heart team confirmed the subject is at high risk for tricuspid valve surgery&#xD;
             (euroSCORE II ≥ 7.0%) and the subject will get benefit from the intervention.&#xD;
&#xD;
          4. Subjects must guarantee they won't participate in any other clinical trial for a&#xD;
             period of one year after the intervention.&#xD;
&#xD;
          5. Subjects are with New York Heart Association (NYHA) Functional Class III or IV.&#xD;
&#xD;
          6. Subjects are with normal left heart function (EF ≥ 50%).&#xD;
&#xD;
          7. No indications for left-sided or pulmonary valve intervention.&#xD;
&#xD;
          8. Subjects must have severe or greater tricuspid regurgitation ( the vena contracta (VC)&#xD;
             width ≥ 7 mm or the effective regurgitant orifice area (EROA) ≥ 40 mm2), which&#xD;
             confirmed by the Echocardiography Core Lab (ECL) via transthoracic echocardiogram&#xD;
             (TTE).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with pulmonary hypertension (systolic pressure ≥ 55mmHg determined by right&#xD;
             heart catheterization).&#xD;
&#xD;
          2. Subjects with previous transcatheter or surgical tricuspid valve procedure.&#xD;
&#xD;
          3. Subjects with tricuspid stenosis or other anatomy disorders that unsuitable for the&#xD;
             procedure.&#xD;
&#xD;
          4. Subjects with depressed right heart function (tricuspid annular plane systolic&#xD;
             excursion (TAPSE) &lt; 10mm or right ventricle fractional area change (FAC) &lt; 20%).&#xD;
&#xD;
          5. Subjects with aortic stenosis (mean ΔP≥ 40mmHg or aortic valve area ≤ 1 cm2), aortic&#xD;
             regurgitation (≥ 3+), mitral stenosis (mitral valve area ≤1.5 cm2) or mitral&#xD;
             regurgitation (≥ 3+).&#xD;
&#xD;
          6. Subjects with active endocarditis or other infectious diseases.&#xD;
&#xD;
          7. Subjects with untreated severe coronary artery disease.&#xD;
&#xD;
          8. Subjects with percutaneous coronary intervention, cerebrovascular accident or surgical&#xD;
             intervention within 3 months of the date of the procedure.&#xD;
&#xD;
          9. Subjects with coagulation disorders.&#xD;
&#xD;
         10. Subjects with known allergy, hypersensitivity or contraindication to the material or&#xD;
             drugs used in the procedure.&#xD;
&#xD;
         11. Subjects with cognitive disorders that can not cooperate the study or follow-up.&#xD;
&#xD;
         12. Subjects with less than 12 months life expectancy because of non-cardiac conditions.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhiyun Xu, MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Changhai Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shengshou Hu, MD.</last_name>
    <role>Study Chair</role>
    <affiliation>Fu Wai Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fanglin Lu, MD.</last_name>
    <role>Study Director</role>
    <affiliation>Changhai Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhao An, MD.</last_name>
    <phone>+8613761420325</phone>
    <email>anzhao1@yeah.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fan Qiao, MD.</last_name>
    <phone>+8613564620805</phone>
    <email>qiaofan@smmu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xu Meng, MD.</last_name>
      <phone>010-64456260</phone>
      <email>mxu@263.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fu Wai Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiangbin Pan, MD.</last_name>
      <phone>010-68314466</phone>
      <email>xiangbin428@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangdong Provincial People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huiming Guo, MD.</last_name>
      <email>guohuiming@vip.tom.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wuhan Union Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nianguo Dong, MD.</last_name>
      <email>ng_dong@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xijing Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian Yang, MD.</last_name>
      <email>yangjian1212@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Shiqiang Yu, MD.</last_name>
      <email>yushiq@fmmu.edu.cn</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Changhai Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhiyun Xu, MD.</last_name>
      <phone>021-31166666</phone>
      <email>zhiyunx@smmu.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>West China Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yingqiang Guo, MD.</last_name>
      <phone>+86 028 85421833</phone>
    </contact>
    <contact_backup>
      <last_name>Mao Chen, MD.</last_name>
      <email>hmaochen@vip.sina.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianan Wang, MD.</last_name>
      <email>wangjianan111@zju.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>June 16, 2020</study_first_submitted>
  <study_first_submitted_qc>June 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2020</study_first_posted>
  <last_update_submitted>November 16, 2020</last_update_submitted>
  <last_update_submitted_qc>November 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Changhai Hospital</investigator_affiliation>
    <investigator_full_name>Zhiyun Xu</investigator_full_name>
    <investigator_title>Chair of Department of Cardiovascular Surgery</investigator_title>
  </responsible_party>
  <keyword>Tricuspid Regurgitation</keyword>
  <keyword>LuX-Valve</keyword>
  <keyword>Transcatheter Valve Replacement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tricuspid Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

